Drug Type CAR-T |
Synonyms Trispecific CD19-CD20-CD22–targeting duoCAR-T cells(Lentigen) |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators), CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Preclinical | United States | 24 Mar 2021 |